Mantle Cell Lymphoma

Closer to a Cure for Mantle Cell Lymphoma

September 25th 2020, 6:00pm


Mantle Cell Lymphoma (MCL), as described in this issue of CURE®, has an interesting and inspiring story. It was one of the first cancers known to have a genetic abnormality-chromosomal translocation t(11;14).

Advances in the Treatment of Mantle Cell Lymphoma are Greatly Improving the Long-Term Outlook for Patients

September 22nd 2020, 6:00pm


Exciting advances in treatment options for patients with mantle cell lymphoma are greatly improving the outlook for long-term remissions.

Cirmtuzumab Combinations Show Potential in Treatment of Mantle Cell Lymphoma

September 9th 2020, 9:00pm


Dr. Lori A. Leslie discuses the potential of combination therapies with the emerging agent cirmtuzumab for patients with mantle cell lymphoma.

Bendamustine-Rituxan Combination Shows Promise in Frontline Treatment of Most Patients with Mantle Cell Lymphoma

September 2nd 2020, 1:00pm


“Moving forward, (bendamustine and Rituxan) will likely become a common backbone for the incorporation of other cytotoxic or novel agents in an attempt to further improve outcomes while maintaining an effective, safe, and ideally outpatient regimen for MCL,” the authors wrote.

The Latest News and Updates in Mantle Cell Lymphoma

August 11th 2020, 1:00pm


A roundup of the latest news and updates for patients with mantle cell lymphoma from CURE®.

Options for Patients with Mantle Cell Lymphoma Are 'Exploding', Expert Says

August 10th 2020, 7:00pm


“It really is an exciting time for patients with lymphoma, because the options are just really exploding at a very encouraging rate,” said Dr. Lori A. Leslie.

Approval of First CAR T-Cell Therapy for Relapsed/Refractory MCL to Change How Patients are Treated 'Forever and for the Better'

August 4th 2020, 10:00pm


“The FDA approval of (Tecartus) will change the way we treat patients with relapsed MCL forever and for the better,” said Dr. Michael Wang.

5 Recent FDA Approvals Patients with Cancer May Have Missed

August 3rd 2020, 7:00pm


The Food and Drug Administration has had a busy summer, approving new agents to treat a variety of cancers. Here are five recent approvals that patients with cancer may have missed.

No 'One Great Answer' When it Comes to What Rights Those Affected By Cancer Have When Returning to Work Amid COVID-19

July 29th 2020, 7:00pm


There are some job protected options for patients with cancer, survivors and caregivers to consider when it comes to returning to work during the COVID-19 pandemic. But, as one cancer rights attorney notes, there are many challenges to those options.

FDA Approves First CAR T-Cell Therapy, Tecartus, for Relapsed or Refractory Mantle Cell Lymphoma

July 24th 2020, 10:44pm


The FDA’s approval of Tecartus for adults with relapsed or refractory mantle cell lymphoma (MCL) is based on data that showed that the CAR T-cell therapy induced a response in 87% of patients.